Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Antiviral Drugs Advisory Committee

Executive Summary

On July 20, will discuss data supporting supplemental NDAs for Burroughs Wellcome's Retrovir (zidovudine, AZT) for protection against maternal-fetal transmission of HIV. The committee will review data from SNDAs 19-655/023, 19-910/011 and 19-951/003 at Parklawn, conference rooms G, H, I & J. Open committee discussion begins at 8 a.m.; the open public hearing begins at 11 a.m. The ACTG 076 study of AZT for use in preventing maternal-fetal transmission of HIV found that when both mother and infant received AZT, the rate of transmission was reduced to 8.3% as compared to the placebo group transmission rate of 25.5% ("The Pink Sheet" Feb. 28, T&G-6)
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS024674

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel